Related Experiment Video
Updated: Aug 5, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Statins Safety Signals: From Precautions to Proportionate Evidence-Based Labeling
Médéa Locquet1, Jonathan Douxfils2, Patrizio Lancellotti3
1Department of Biomedical Sciences, Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium.
Clinical Pharmacology and Therapeutics
|July 28, 2026
Summary
A large meta-analysis clarifies statin side effects, showing fewer harms than previously thought. This finding impacts drug safety communication and patient adherence to cholesterol-lowering medications.
Area of Science:
- Pharmacovigilance
- Cardiovascular Medicine
- Evidence-Based Medicine
Background:
- Statins are widely prescribed for cardiovascular disease prevention.
- Concerns about statin-associated adverse drug reactions (ADRs) persist.
- Comprehensive evidence on statin ADRs is crucial for clinical practice and public health.
Purpose of the Study:
- To provide the most comprehensive randomized evidence on statin-associated adverse drug reactions.
- To clarify the harms confidently attributable to statins.
- To examine challenges in pharmacovigilance and regulatory risk communication regarding statins.
Main Methods:
- Conducted a meta-analysis of randomized controlled trials (RCTs) on statin use.
- Synthesized evidence on adverse drug reactions associated with statin therapy.
- Evaluated the certainty of evidence for reported harms.
Main Results:
- Substantially narrowed the list of harms confidently attributable to statins.
- Identified specific adverse drug reactions with varying levels of certainty.
- Highlighted the impact of low-certainty evidence on risk communication.
Conclusions:
- Precautionary labeling based on low-certainty evidence may lead to adverse outcomes.
- Amplification of nocebo effects can reduce adherence to preventive statin therapy.
- Improved pharmacovigilance and risk communication are needed to balance benefits and harms, especially for vulnerable populations.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...